Navigation Links
Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
Date:11/8/2007

SOUTH SAN FRANCISCO, Calif., Nov. 8 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, Chairman and CEO, is scheduled to present a corporate overview at the Piper Jaffray 19th Annual Healthcare Conference on Tuesday, November 27, 2007 at 3:00 p.m. (Eastern Time) at the Pierre Hotel in New York.

To access the live audio broadcast or the subsequent archived recording, log on to http://www.monogrambio.com and go to the investor relations section ("Investors/Media" tab) and click on the "Events & Webcasts" link provided on the sidebar menu on the page.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624-4576 Tel: 415 677-2700

amerriweather@monogrambio.com

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
8. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- The UPMC Center for Health Security today announced ... Leaders in Biosecurity Initiative (ELBI). As part of our ... biosecurity, UPMC has selected 28 US and international emerging ... including biological science, medicine, policy, the military, think tanks ... vision and support of the Defense Threat Reduction Agency ...
(Date:3/4/2015)... 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the ... a collaborative research program with Emerald Logic, ... Collective Evolution Technology (FACET), Emerald Logic analyzed ... obtained from each of 798 patients who ... trials ASSERT, SUSTAIN and ASSURE. The objective ...
(Date:3/4/2015)... SEOUL, South Korea , March 4, 2015 /PRNewswire/ ... based biopesticide company, in August of last year. As ... with Kyung Bon Koo continuing his role ... Selakovic , President of Vegalab S.A., will work alongside ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 ...
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... molecular diagnostics that target the underlying mechanisms of cancer, ... period ended December 31, 2014. Effective July ... from May 31 to December 31. As a result ... are for the quarter and the seven months ended ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... 12, 2011 Cord Blood America, Inc. ( www.cordblood-america.com ) ... company focused on bringing the life saving potential of stem ... is reducing the monthly payment in its unique "Afford-A-Cord" storage ... reduces the initial cost of storing umbilical cord blood stem ...
... 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX ... company focused on researching, developing, manufacturing and marketing biopharmaceutical ... first quarter ended March 31, 2011. ... Total net revenues increased by 22.7% ...
... 11, 2011 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today reported financial and operating results ... For the first quarter of 2011 PharmAthene recognized revenue ... period of 2010.  Revenues for the most recent quarter consisted ...
Cached Biology Technology:Cord Blood America Reduces "Afford-A-Cord" Program Charges; New Buyers Anticipated 23SBio Inc. Announces Unaudited First Quarter 2011 Results 23SBio Inc. Announces Unaudited First Quarter 2011 Results 33SBio Inc. Announces Unaudited First Quarter 2011 Results 43SBio Inc. Announces Unaudited First Quarter 2011 Results 53SBio Inc. Announces Unaudited First Quarter 2011 Results 63SBio Inc. Announces Unaudited First Quarter 2011 Results 73SBio Inc. Announces Unaudited First Quarter 2011 Results 83SBio Inc. Announces Unaudited First Quarter 2011 Results 93SBio Inc. Announces Unaudited First Quarter 2011 Results 103SBio Inc. Announces Unaudited First Quarter 2011 Results 113SBio Inc. Announces Unaudited First Quarter 2011 Results 123SBio Inc. Announces Unaudited First Quarter 2011 Results 13PharmAthene Reports First Quarter 2011 Financial and Operating Results 2PharmAthene Reports First Quarter 2011 Financial and Operating Results 3PharmAthene Reports First Quarter 2011 Financial and Operating Results 4PharmAthene Reports First Quarter 2011 Financial and Operating Results 5PharmAthene Reports First Quarter 2011 Financial and Operating Results 6
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
(Date:2/25/2015)... 2015  ABC Financial Services (ABC), the leading ... and Fitness Industry, today announced enhancements to their ... latest upgrade includes advances to the agreement section ... via Identity One fingerprint biometrics. The features will ... displays at the International Health, Racquet & Sportsclub ...
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... German . Tomislav Domazet-Loo and Diethard Tautz from ... have systematically analysed the time of emergence for a large ... Their studies show for the first time that the majority ... of the first cells. The search for further genes, particularly ...
... cluster study The Australian Imaging, Biomarker and Lifestyle ... first collaborative research agreement with a major strategic alliance ... of its type, and aims to better understand the ... for early diagnosis. The study is an initiative ...
... tested at the National Institute of Standards and ... recent paper,* NIST scientists used surface-enhanced Raman spectroscopy ... qualities that make them superior for chemical and ... may one day be used in a range ...
Cached Biology News:Genetic based human diseases are an ancient evolutionary legacy 2Alzheimer's disease research attracts first partner 2Gold nanostars outshine the competition 2
... Adept CE 4100 high pressure pump ... precision, with software drive compensation, reducing pulsing ... are selectable in 0.001mL steps. , The ... and bio-compatible., Pumps may be programmed from ...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: